Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: Potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 5, 2009, Pages 384-392

  Oizumi, Takefumi ^b   Yamaguchi, Kouji ^b   Funayama, Hiromi ^b   Kuroishi, Toshinobu ^b   Kawamura, Hiroshi ^b   Sugawara, Shunji ^b   Endo, Yasuo ^a,b  

^a Graduate School of Dentistry   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE NECROSIS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FEMALE; INJECTION SITE NECROSIS; JAW OSTEONECROSIS; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DIPHOSPHONATES; DRUG COMBINATIONS; DRUG ERUPTIONS; FEMALE; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; NITROGEN; OSTEONECROSIS; SKIN; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS;

EID: 64549134703     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00374.x     Document Type: Article

References (40)

1. Geddes AD, D'Souza SM, Ebetino FH, Kenneth JI. Bisphosphonates: structure-activity relationships and therapeutic implications. In : Heershe NM, Kanis JK (eds). Bone and Mineral Research, vol. 8. Elsevier Science BV, Amsterdam, Holland, 1994 265 306.
2. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Mönkkönen J et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000 88 : 2961 78.
3. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006 12 (20 Suppl 6222s 30s.
4. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006 13 : 7 26.
5. Dieli F, Vermijlen D, Fulfare F, Caccamo N, Meraviglia S, Cicero G et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007 67 : 7450 7.
6. Adami S, Bhalla AK, Dorizzi R, Montesani F, Rosini S, Salvagno G et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int 1987 41 : 326 31.
7. Siris E. Bisphosphonates and iritis. Lancet 1993 341 : 436 7.
8. Macarol V, Frauenfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthamol 1994 118 : 220 4.
9. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M et al. Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996 18 : 133 9.
10. Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997 29 : 56 62.
11. Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997 61 : 386 92.
12. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM. Paget's disease of bone: early and late responses to three modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 1987 295 : 1301 5.
13. Schweitzer DH, Ruit MOVD, Pruijm GVD, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995 10 : 956 62.
14. Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004 35 : 231 4.
15. Ruggiero S, Mebrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004 62 : 527 34.
16. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006 144 : 753 61.
17. Pazianas M, Miller P, Blimentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Therapeut 2007 29 : 1548 58.
18. Shimahara M, Ariyoshi Y, Imai Y, Mizuki H, Shimada J, Furusawa K et al. A survey of bisphosphonate-related osteomyelitis/osteonecrosis of the jaw. Jap J Oral Surg 2007 53 : 16 24 (Japanese, abstract in English).
19. Novartis home page http://www.novartis.co.jp/product/zom/te/te- arezom0607.html July 2006.
20. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005 63 : 682 9.
21. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006 7 : 508 14.
22. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006 2 : 7 14.
23. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006 81 : 1047 53.
24. Endo Y, Nakamura N, Kikuchi T, Shinoda H, Takeda K, Nitta Y et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 1993 52 : 248 54.
25. Nakamura M, Yagi H, Endo Y, Kosugi H, Ishii T, Itoh T. A time kinetic study of the effect of aminobisphosphonate on murine haemopoiesis. Br J Haematol 1999 107 : 779 90.
26. Yamaguchi K, Motegi K, Iwakura Y, Endo Y. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol 2000 130 : 1646 54.
27. Funayama H, Mayanagi H, Takada H, Endo Y. Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate. Arch Oral Biol 2000 45 : 787 95.
28. Deng X, Yu Z, Funayama H, Shoji N, Sasano T, Iwakura Y et al. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol Appl Pharmacol 2006 213 : 64 73.
29. Endo Y, Shibazaki M, Nakamura M, Kosugi H. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol 1999 126 : 903 10.
30. Yu Z, Funayama H, Deng X, Kuroishi T, Sasano T, Sugawara S et al. Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model. Basic Clin Pharmacol Toxicol 2005 97 : 222 39.
31. Mönkkönen J, Koponen H-M, Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 1989 65 : 294 8.
32. Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992 20 : 473 8.
33. Monma Y, Funayama H, Mayanagi H, Endo Y. Effects of weekly administrations of alendronate + clodronate on young mouse tibia: localized action at the proximal growth plate. Calcif Tissue Int 2004 74 : 115 21.
34. Funayama H, Ohsako M, Monma Y, Mayanagi H, Sigawara S, Endo Y. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate. Calcif Tissue Int 2005 76 : 448 57.
35. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991 88 : 2095 105.
36. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonates drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006 69 : 1624 32.
37. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008 42 : 848 60.
38. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD et al. Structure-activity relationship for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Therapeut 2001 296 : 235 42.
39. Deng X, Yu Z, Funayama H, Yamaguchi K, Sasano T, Sugawara S et al. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFα, macrophages, and T-cells. International Immunopharmacol 2007 7 : 152 61.
40. Lipton A. Toward new horizons: the future of bisphosphonates therapy. Oncologist 2004 9 (Suppl 4 38 47.